Quibim, a Valencia-based healthtech startup, has raised $50 million in a Series A round of funding to further develop its AI-driven medical imaging platform. The investment will enable the company to accelerate its growth in the US market and expand its product offerings.

The funding round, led by Spanish venture capital firm Asabys and private equity firm Buenavista, brings Quibim's total funding to around $70 million since its inception. The company's AI models are designed to enhance diagnostic accuracy and disease detection from visual data procured from X-rays, CT scans, and MRIs.

Quibim's flagship product, QP-Prostate, is a prime example of its innovative approach. The product has received FDA 510(k) clearance and is designed to improve prostate cancer detection. The company is also working on separate products for the brain, liver, breast, and lung, demonstrating its commitment to advancing medical imaging across various disease areas.

Beyond medical imaging, Quibim offers QP-Insights, a platform for processing multi-omics data in clinical trials and related studies. This comprehensive approach enables the company to provide a more detailed understanding of the human body, ultimately driving precision health.

Quibim's long-term vision is to create digital twins of the entire human body, serving as dynamic models that help the medical community better understand human physiology. This ambitious goal begins at the organ and lesion level, as demonstrated by QP-Prostate. By achieving this vision, Quibim aims to revolutionize diagnostics and improve patient outcomes.

The company's expansion into the US market is a critical milestone in its growth strategy. Quibim has already established partnerships with prestigious institutions such as Stanford University and Harvard-affiliated integrated healthcare system Mass General Brigham. The company has also received support from industry leaders, including Philips, which plans to integrate Quibim's AI models into its scanners.

Quibim's CEO and co-founder, Ángel Alberich-Bayarri, emphasized the significance of the company's global expansion, stating, "Our mission is to turn imaging into a catalyst for precision health. Our global expansion into the US is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes."

The participation of prominent investors, including Amadeus Capital Partners, Apex Ventures, Partech, and iPod and iPhone co-creator Tony Fadell, demonstrates the confidence in Quibim's innovative approach and its potential to transform the healthcare industry.

As AI continues to make inroads into healthcare, Quibim's latest funding round highlights the company's position at the forefront of medical imaging innovation. With its sights set on the US market, Quibim is poised to make a significant impact on the global healthcare landscape.